CG Oncology (CGON) is back in focus as investors look ahead to key data from its Phase 3 PIVOT-006 trial and a planned regulatory filing for bladder cancer therapy cretostimogene later this year.

Recent excitement around cretostimogene and upcoming conference appearances has not prevented some volatility, with the share price down 20.77% over the past month and 12.78% over 90 days, yet still posting a 31.42% year to date share price return and a very large 1 year total shareholder return of about 2x.

If this kind of biotech catalyst story interests you, it could be a useful moment to scan other healthcare opportunities through the 39 healthcare AI stocks

With CG Oncology shares still up 31.42% year to date, trading at a sizeable discount to an average analyst price target of US$90.29 and flagged as undervalued on some intrinsic metrics, investors may ask whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Preferred Price to Book Multiple of 4.4x: Is it justified?

On simple valuation checks, CG Oncology screens as good value against some measures. However, its 4.4x P/B ratio is higher than the wider US biotech peer average of 2.4x.

The P/B ratio compares the market value of the company to its book value. This metric is often used for early stage or loss-making biopharma companies where earnings are not yet a stable anchor. A 4.4x P/B suggests investors are putting a sizeable premium on CG Oncology’s asset base, pipeline and prospects relative to its stated net assets.

Relative to CG Oncology’s own peer set, the stock is described as good value based on its 4.4x P/B versus a peer average of 4.5x. This implies the market is pricing it broadly in line with close comparables, while still paying a higher multiple than the broader US biotech group at 2.4x. Alongside that, the SWS DCF model flags the shares as trading at an 85.7% discount to an estimated future cash flow value of $383.13 per share, which is far above the last close of $54.92 and indicates the market price could move a long way before lining up with that model’s implied value.

Result: Price to book ratio of 4.4x (UNDERVALUED)

However, investors still face meaningful risk if key cretostimogene trials disappoint or if ongoing losses of US$186.745 million limit future funding options.

Another way to look at value

The SWS DCF model takes a very different angle from the 4.4x P/B view, estimating CG Oncology’s future cash flow value at $383.13 per share versus the current $54.92. That points to an 85.7% discount, which raises a key question: is the market being cautious, or is the model too optimistic?

For a closer look at how this future cash flow estimate is built and what assumptions sit underneath it, check out the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment around CG Oncology is mixed. If you are interested, take a closer look at the numbers and form your own view with the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you like this kind of focused, catalyst driven story, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.

• Spot potential value candidates early by scanning 47 high quality undervalued stocks that combine quality fundamentals with pricing that may still offer room for upside.
• Strengthen your portfolio’s foundations by reviewing solid balance sheet and fundamentals stocks screener (46 results) that emphasize financial resilience and healthy fundamentals.
• Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems that the market may not be paying close attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.